Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G C Toner

Showing results (31-40 of 56) with videos related to

Pageof 6
Sort By:
American Journal of Clinical Oncology|June 17, 1998
Dose escalation study of carboplatin and cyclophosphamide with filgrastim support: a phase I studyG C Toner, M Green, J F Bishop, et al.
Journal of the National Cancer Institute|September 18, 1996
Cremophor pharmacokinetics in patients receiving 3-, 6-, and 24-hour infusions of paclitaxelD Rischin, L K Webster, M J Millward, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|January 1, 1994
Phase I trial of intravenous and intraperitoneal administration of granulocyte-macrophage colony-stimulating factorG C Toner, J L Gabrilove, M Gordon, et al.
Investigational New Drugs|March 11, 2006
Phase II study of vinflunine in patients with metastatic renal cell carcinomaD Goldstein, S P Ackland, D R Bell, et al.
The Medical Journal of Australia|May 19, 1997
Australian multicentre phase II trial of paclitaxel in women with metastatic breast cancer and prior chemotherapyM Michael, J F Bishop, J A Levi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1996
Phase II trial of a 3-hour infusion of paclitaxel in previously untreated patients with advanced non-small-cell lung cancerM J Millward, J F Bishop, M Friedlander, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 6, 1999
Phase I and subsequent phase II study of filgrastim (r-met-HuG-CSF) and dose intensified cyclophosphamide plus epirubicin in patients with non-Hodgkin's lymphoma and advanced solid tumorsS M Talbot, D A Westerman, A P Grigg, et al.
Oncology (Williston Park, N.Y.)|April 1, 1997
Paclitaxel as first-line treatment for metastatic breast cancer. The Taxol Investigational Trials Group, Australia and New ZealandJ F Bishop, J Dewar, G C Toner, et al.
Cancer|January 15, 1997
Residual pulmonary masses after chemotherapy for metastatic nonseminomatous germ cell tumor. Prediction of histology. ReHiT Study GroupE W Steyerberg, H J Keizer, J E Messemer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1995
Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: multivariate analysis of individual patient data from six study groupsE W Steyerberg, H J Keizer, S D Fosså, et al.
Pageof 6

Showing results (31-40 of 56) with videos related to

Sort By:
Pageof 6
American Journal of Clinical Oncology|June 17, 1998
Dose escalation study of carboplatin and cyclophosphamide with filgrastim support: a phase I studyG C Toner, M Green, J F Bishop, et al.
Journal of the National Cancer Institute|September 18, 1996
Cremophor pharmacokinetics in patients receiving 3-, 6-, and 24-hour infusions of paclitaxelD Rischin, L K Webster, M J Millward, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|January 1, 1994
Phase I trial of intravenous and intraperitoneal administration of granulocyte-macrophage colony-stimulating factorG C Toner, J L Gabrilove, M Gordon, et al.
Investigational New Drugs|March 11, 2006
Phase II study of vinflunine in patients with metastatic renal cell carcinomaD Goldstein, S P Ackland, D R Bell, et al.
The Medical Journal of Australia|May 19, 1997
Australian multicentre phase II trial of paclitaxel in women with metastatic breast cancer and prior chemotherapyM Michael, J F Bishop, J A Levi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1996
Phase II trial of a 3-hour infusion of paclitaxel in previously untreated patients with advanced non-small-cell lung cancerM J Millward, J F Bishop, M Friedlander, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 6, 1999
Phase I and subsequent phase II study of filgrastim (r-met-HuG-CSF) and dose intensified cyclophosphamide plus epirubicin in patients with non-Hodgkin's lymphoma and advanced solid tumorsS M Talbot, D A Westerman, A P Grigg, et al.
Oncology (Williston Park, N.Y.)|April 1, 1997
Paclitaxel as first-line treatment for metastatic breast cancer. The Taxol Investigational Trials Group, Australia and New ZealandJ F Bishop, J Dewar, G C Toner, et al.
Cancer|January 15, 1997
Residual pulmonary masses after chemotherapy for metastatic nonseminomatous germ cell tumor. Prediction of histology. ReHiT Study GroupE W Steyerberg, H J Keizer, J E Messemer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1995
Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: multivariate analysis of individual patient data from six study groupsE W Steyerberg, H J Keizer, S D Fosså, et al.
Pageof 6